Key points
Vadadustat (brand name Vafseo) is a tablet for anaemia of chronic kidney disease that makes the body produce its own erythropoietin; the FDA approved it in March 2024 for adults on dialysis for at least three months.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Anaemia in adults on dialysis for at least three months | raises haemoglobin: the body produces its own erythropoietin instead of receiving the finished hormone by injection | INNO2VATE (NEJM, 2021), 3,923 patients on dialysis: no worse than the standard injection, darbepoetin alfa, on both haemoglobin and cardiovascular events — 18.2% versus 19.3%, hazard ratio 0.96 (95% CI 0.83–1.11) [1] |
| Convenience on dialysis | a tablet instead of injections; no cold chain needed for storage | — |
| Iron metabolism | alongside erythropoietin, the tuning of iron metabolism switches on | — |
How it helps
Why haemoglobin falls in kidney disease
The kidneys are not only a filter. They produce erythropoietin, the hormone that tells the bone marrow to make red cells. As the kidneys fail the instruction stops arriving, and anaemia follows: fatigue, breathlessness, poor exercise tolerance.
For decades the answer was direct — inject the missing hormone. It works, but it requires injections, cold storage and careful dose titration.
How vadadustat works
The body has a built-in oxygen sensor: the HIF factor. When oxygen is plentiful a dedicated enzyme continuously degrades it. When oxygen is scarce — at altitude, for instance — the enzyme slows, HIF accumulates and switches on a programme: more erythropoietin, better iron handling, more active blood formation.
Vadadustat blocks that enzyme. The body behaves as if it had gone up a mountain, though the person has gone nowhere. From there it is the patient's own physiology doing the work, not an externally supplied hormone.
An important consequence: not only erythropoietin production switches on but the accompanying tuning of iron metabolism — the mechanism sits closer to the natural one than an injection of the finished hormone does.
What the trials showed
The development programme was built honestly: the same molecule was tested in two large trials — dialysis patients separately, pre-dialysis patients separately. In both cases the comparator was darbepoetin alfa, the standard injection, not placebo.
| INNO2VATE (dialysis) | PRO2TECT (non-dialysis) | |
|---|---|---|
| Patients | 3,923 | 3,476 |
| Comparator | Darbepoetin alfa | Darbepoetin alfa |
| Haemoglobin: non-inferior | Yes | Yes |
| Cardiovascular safety: non-inferior | Yes (HR 0.96) | No (HR 1.17, margin 1.25) |
| Regulatory outcome | Indication granted | No indication |
Why the indication is dialysis only
A regulator approves where the evidence held. Hence the unusually narrow wording of the indication: dialysis for at least three months. Not kidney disease, not anaemia in CKD — precisely the population in which the positive trial was run.
Where it sits among its relatives
| Drug | United States | Elsewhere |
|---|---|---|
| Vadadustat (Vafseo) | Approved, dialysis only | Approved in Japan, EU |
| Daprodustat (Jesduvroq) | Approved, dialysis only | Approved in Japan |
| Roxadustat (Evrenzo) | FDA refused | Approved in Japan, China, EU |
The pattern is visible: the US regulator accepted the class, but admitted only those molecules and those populations where the cardiovascular safety data were convincing. The class mechanism and the roxadustat story are covered in a separate guide.
How to take it
| Parameter | Detail |
|---|---|
| Formulation | Tablets |
| Who | Adults on dialysis ≥ 3 months |
| Storage | Ordinary; no cold chain |
| Monitoring | Haemoglobin, ferritin, transferrin saturation, liver tests |
| Iron | Usually required — stimulation without raw material is pointless |
| Timing | At least 1 hour before oral iron products, including iron-containing phosphate binders [4] |
Who should see a doctor first
Vadadustat is a prescription drug started by a nephrologist; switching from injections to tablets is also the nephrologist's decision.
A separate word on the goal of treatment: haemoglobin in kidney disease is not pushed to the level of a healthy person. Attempts at full normalisation produced more cardiovascular events in earlier trials, and that is a property of the entire class of agents stimulating blood formation. The target range is deliberately modest, and the nephrologist sets it.
The FDA label carries a boxed warning: an increased risk of death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access. That is why the lowest dose sufficient to reduce the need for red blood cell transfusions is used. Liver tests (ALT, AST, bilirubin) are checked before treatment starts, monthly for the first 6 months and then as clinically indicated [4].
Who it is not for
▸ Patients with kidney disease not yet on dialysis: in the PRO2TECT trial a higher risk of cardiovascular events could not be ruled out in them (hazard ratio 1.17; 95% CI 1.01–1.36), so under the current US indication the drug is not prescribed to them [2].
▸ People with uncontrolled blood pressure — the label lists this as a contraindication [4].
▸ Anyone whose iron stores are not replenished: iron first, stimulation second.
▸ Anyone expecting a normal haemoglobin: the goal of therapy is different and deliberately more modest.
Bottom line
▸ Mechanism: mimicking oxygen shortage switches on the body's own erythropoietin production instead of injecting the hormone.
▸ Dialysis patients: equivalent to the standard injection on both haemoglobin and cardiovascular events.
▸ The shape of the approval mirrors the shape of the evidence: the indication is dialysis, where the data held.
▸ Iron is mandatory — otherwise there is nothing to stimulate.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Eckardt KU, et al. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021;384(17):1601–1612. PMID 33913638
2. Chertow GM, et al. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021;384(17):1589–1600. PMID 33913637
3. Sarnak MJ, et al. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023;38(10):2358–2367. PMID 37096396
4. VAFSEO (vadadustat) — US Prescribing Information, Akebia Therapeutics.
Source: Vadadustat (Vafseo): Why a Pill for Kidney Anaemia Was Approved Only for Dialysis Patients — universum.earth. Dr. Pereligyn.
